|
Based on the information provided, no conclusions can be made.As reported, the patient experienced post-op complication of erythema.The patient¿s condition resolved without intervention.Medical affairs has assessed the patient¿s postoperative course as being serious and likely related to the study device.Review of the device history records confirmed the device was manufactured to specification.Note: this mdr report is related to a retrospective study conducted to proactively gather real-world evidence on the use and safety of the p4hb product family, including galaflex scaffold, galaflex 3d, and galaflex 3dr.All safety events from the study are adjudicated by the bd medical monitor for an independent assessment of severity and relatedness.In an abundance of caution, events for which relatedness cannot be ruled out are processed for mdr reporting.
|
|
Per clinical trial (b)(6): on (b)(6) 2018, patient underwent left breast central mound reduction and right breast mastopexy using a full vertical and horizontal t incision.2 pieces of galaform (galaflex 3dr) were used.No concomitant procedures were done.On (b)(6) 2018, left breast erythema/redness was reported.No treatment was given.Resolved on (b)(6) 2018 without sequelae.Review by medical affairs identifies the erythema as likely related to the device and serious.
|